136 related articles for article (PubMed ID: 32509919)
1. The Patient Bomb: Sustained Viral Response after Hepatitis C in Cirrhosis.
Tato Marinho RAR
GE Port J Gastroenterol; 2020 Apr; 27(3):147-148. PubMed ID: 32509919
[No Abstract] [Full Text] [Related]
2. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
Asselah T; Bourgeois S; Pianko S; Zeuzem S; Sulkowski M; Foster GR; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Gane EJ; Feld JJ; Mangia A
Liver Int; 2018 Mar; 38(3):443-450. PubMed ID: 28756625
[TBL] [Abstract][Full Text] [Related]
3. An unfortunate failure: multifocal hepatocellular carcinoma in a non-cirrhotic patient with chronic hepatitis C treated with ledipasvir/sofosbuvir.
Soliman MS; Soliman YY; Ahmad Q; Yarlagadda R
J Community Hosp Intern Med Perspect; 2018; 8(3):167-169. PubMed ID: 29915662
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
Flower B; Hung LM; Mccabe L; Ansari MA; Le Ngoc C; Vo Thi T; Vu Thi Kim H; Nguyen Thi Ngoc P; Phuong LT; Quang VM; Dang Trong T; Le Thi T; Nguyen Bao T; Kingsley C; Smith D; Hoglund RM; Tarning J; Kestelyn E; Pett SL; van Doorn R; Van Nuil JI; Turner H; Thwaites GE; Barnes E; Rahman M; Walker AS; Day JN; Chau NVV; Cooke GS
Elife; 2023 Jan; 12():. PubMed ID: 36622106
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study.
Choi IS; Kim KM; Shim SG
Arab J Gastroenterol; 2021 Mar; 22(1):23-27. PubMed ID: 33223391
[TBL] [Abstract][Full Text] [Related]
6. Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.
Louie V; Latt NL; Gharibian D; Sahota A; Yanny BT; Mittal R; Bider-Canfield Z; Cheetham TC
Perm J; 2017; 21():16-096. PubMed ID: 28368787
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma in a hepatitis C patient with sustained viral response and no fibrosis.
Tabibian JH; Landaverde C; Winn J; Geller SA; Nissen NN
Ann Hepatol; 2009; 8(1):64-7. PubMed ID: 19221537
[TBL] [Abstract][Full Text] [Related]
8. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.
Tmu N; Kumar A; Sharma P; Singla V; Bansal N; Arora A
J Clin Exp Hepatol; 2019; 9(1):4-12. PubMed ID: 30765933
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness and safety of sofosbuvir/velpatasvir combination ± ribavirin in the treatment of Chinese adults with chronic hepatitis C virus infection].
Li JP; Chen XF; Yan Q; Zhang YJ; Xie ZW; Xia Y; Guan YJ
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):831-837. PubMed ID: 33105927
[No Abstract] [Full Text] [Related]
10. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
Nair S; Satapathy SK; Gonzalez HC
Exp Clin Transplant; 2017 Jun; 15(3):314-319. PubMed ID: 26926117
[TBL] [Abstract][Full Text] [Related]
12. Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis.
Sakamori R; Yamada R; Shinkai K; Doi A; Tahata Y; Shigekawa M; Kodama T; Hikita H; Yamada T; Tatsumi T; Takehara T
Intern Med; 2021; 60(5):745-750. PubMed ID: 33642562
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference?
Sarwar S; Khan AA
Pak J Med Sci; 2017; 33(1):37-41. PubMed ID: 28367169
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
[TBL] [Abstract][Full Text] [Related]
15. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
Teegen EM; Globke B; Schott E; Pratschke J; Eurich D
Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590
[TBL] [Abstract][Full Text] [Related]
16. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.
Gheorghe LS; Preda C; Iliescu L; Istratescu D; Chifulescu AE; Pop CS; Trifan A; Stanciu C; Diculescu M; Voiosu T; Baicus C; Tugui L; Iacob S; Tieranu C; Meianu C; Manuc M
J Gastrointestin Liver Dis; 2020 Sep; 29(3):385-390. PubMed ID: 32919421
[TBL] [Abstract][Full Text] [Related]
18. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
Kawaoka T; Imamura M; Morio K; Nakamura Y; Tsuge M; Nelson Hayes C; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Ohdan H; Chayama K
Clin J Gastroenterol; 2017 Apr; 10(2):179-184. PubMed ID: 28224470
[TBL] [Abstract][Full Text] [Related]
19. Outcome of hepatitis C-related liver transplantation in direct-acting antiviral era.
Choudhary NS; Saraf N; Saigal S; Rastogi A; Bhangui P; Thiagrajan S; Soin AS
Indian J Gastroenterol; 2020 Dec; 39(6):539-543. PubMed ID: 33230754
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety, and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosis.
Su PS; Wu SH; Chu CJ; Su CW; Lin CC; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2022 Feb; 85(2):152-159. PubMed ID: 34759209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
